COULD THE ACTIVITY OF REDUCED GLUTATHIONE ON CELLULAR IMMUNITY IN ALVEOLAR ENVIRONMENT PROTECT FROM LUNG CANCER? (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

COULD THE ACTIVITY OF REDUCED GLUTATHIONE ON CELLULAR IMMUNITY IN ALVEOLAR ENVIRONMENT PROTECT FROM LUNG CANCER? (MEETING ABSTRACT)

Chest; 100(2, Suppl):41S 1991. Unique Identifier : AIDSLINE ICDB/92679232
Piazza G; Montoli CC; Migliorino GM; DeVincentiis A; Scarpazza G; INRCA, Pneumology Dept., Casatenovo, Italy

Abstract: The oxidant stress may alter cell immunity and has been associated with lung cancer. A premedication with antioxidants protects from the experimental tumor. The reduction of alveolar macrophage activity and CD4/CD8 lymphocyte ratio in bronchoalveolar lavage (BAL) is related to lung cancer and smoking (an important source of oxidants). To check the activity of antioxidants on cell immunity of the alveolar environment before and after administering aerosol-reduced glutathione (600 mg bid for 6 days), we evaluated the CD3, CD4, CD8 lymphocyte subsets and CD4/CD8 ratio in BAL (50 ml of normal saline solution at 37 C for 4x in the middle lobe) and alveolar macrophage phagocytosis (superoxide anion production after phagocytosis of opsonized zymosan). The 10 patients studied (7 males; 3 females) showed an increase in CD4/CD8 ratio (which nevertheless does not reach any statistical significance) and an improvement of alveolar macrophage phagocytosis (33.2 vs 50.7; p less than 0.04). After administering glutathione in an aerosol, our data show immunological changes opposite to those associated with lung cancer, and also might indicate that the protection from lung cancer provided by antioxidant compounds could be produced by improved immune surveillance.

Keywords: Aerosols Antigens, Differentiation, T-Lymphocyte/ANALYSIS Bronchoalveolar Lavage Fluid CD4-CD8 Ratio Female Glutathione/*ADMINISTRATION & DOSAGE Human Immunity, Cellular/*DRUG EFFECTS Lung Neoplasms/*IMMUNOLOGY/METABOLISM/PATHOLOGY Macrophages/IMMUNOLOGY Male Phagocytosis Pulmonary Alveoli/IMMUNOLOGY Receptors, Antigen, T-Cell/ANALYSIS ABSTRACT
920630
M9261023

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .